Rising to the Challenge of Solid Tumors: The Promise of Autologous and Allogeneic TCR T-cell Therapies

The promise of cell therapy for people living with cancer has been realized with several Chimeric Antigen Receptor (CAR) T-cell therapies approved for a range of hematological tumors. However, the challenges presented by solid tumors – including low and heterogenous expression of tumor specific antigen targets and challenging tumor microenvironment – have been associated with limited efficacy, to date, of CAR T-cell therapies for these types of cancer. During this presentation, Dr, Karen Miller, SVP Pipeline Research at Adaptimmune, will talk about the potential of autologous and allogeneic TCR T-cell therapies in clinical trials to treat patients with multiple solid tumor indications. The Company has recently shared data with its most advanced therapy, afamitresgene autoleucel, showing promising efficacy and durability data in synovial sarcoma, which will be used to file a licensing application, and initial data in five solid tumors with a next-generation therapy that will be investigated in Phase 2 trials for people with esophageal, esophagogastric junction and ovarian cancers.